{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:15:00Z","timestamp":1769512500355,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2017ZX10302201-001"],"award-info":[{"award-number":["2017ZX10302201-001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81721002"],"award-info":[{"award-number":["81721002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81371852"],"award-info":[{"award-number":["81371852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772178"],"award-info":[{"award-number":["81772178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.antiviral.2020.104852","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T10:02:31Z","timestamp":1592647351000},"page":"104852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients"],"prefix":"10.1016","volume":"180","author":[{"given":"Rongjuan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changzhu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104852_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2007.06.011","article-title":"Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials","volume":"47","author":"Borroto-Esoda","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104852_bib2","first-page":"2159","article-title":"Guideline on prevention and treatment of chronic hepatitis B in China (2005)","volume":"120","author":"Chinese Society of Hepatology","year":"2007","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.antiviral.2020.104852_bib3","first-page":"13","article-title":"The guideline of prevention and treatment for chronic hepatitis B (2010 Version)","volume":"19","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases & Chinese Medical Association","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi (Chin. J. Hepatol.)"},{"key":"10.1016\/j.antiviral.2020.104852_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104852_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2012.02.003","article-title":"The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation","volume":"54","author":"Ji","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2020.104852_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jmv.23440","article-title":"Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy","volume":"85","author":"Kim","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104852_bib8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jvh.12298","article-title":"The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil","volume":"22","author":"Liu","year":"2015","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104852_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.antiviral.2019.02.012","article-title":"Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients","volume":"164","author":"Liu","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104852_bib10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/liv.13104","article-title":"Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues","volume":"36","author":"Liu","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2020.104852_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP3305","article-title":"Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment","volume":"24","author":"Liu","year":"2019","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104852_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3851\/IMP1679","article-title":"Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B","volume":"15","author":"Liu","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104852_bib13","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1365-2893.2010.01360.x","article-title":"Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection","volume":"18","author":"Liu","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104852_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1080\/22221751.2019.1584018","article-title":"Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice","volume":"8","author":"Liu","year":"2019","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.antiviral.2020.104852_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12072-008-9048-3","article-title":"Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure","volume":"2","author":"Locarnini","year":"2008","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2020.104852_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Long-term monitoring HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104579","article-title":"Investigation of hepatitis B virus (HBV) rtS78T\/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside\/nucleotide analogue treatment","author":"Luo","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104852_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104852_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104852_bib21","doi-asserted-by":"crossref","first-page":"61719","DOI":"10.18632\/oncotarget.18682","article-title":"Additional N-glycosylation mutation in the major hydrophilic region of hepatitis B virus S gene is a risk indicator for hepatocellular carcinoma occurrence in patients with coexistence of HBsAg\/anti-HBs","volume":"8","author":"Qiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.antiviral.2020.104852_bib22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104852_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep.23145","article-title":"Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone","volume":"50","author":"Shim","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2893.2012.01638.x","article-title":"Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen","volume":"20","author":"Svarovskaia","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2020.104852_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na\u00efve patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2006.08.013","article-title":"Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient","volume":"131","author":"Villet","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2020.104852_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"Yang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.21290","article-title":"Evolution of multi-drug resistant hepatitis B virus during sequential therapy","volume":"44","author":"Yim","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104852_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2018.04.003","article-title":"Hepatitis B virus rtA181T\/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T\/sW172* mutation","volume":"154","author":"Zhao","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104852_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939759","article-title":"In vitro models for studying hepatitis B virus drug resistance","volume":"26","author":"Zoulim","year":"2006","journal-title":"Semin. Liver Dis."},{"issue":"S1","key":"10.1016\/j.antiviral.2020.104852_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.12069","article-title":"Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance","volume":"33","author":"Zoulim","year":"2013","journal-title":"Liver Int."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220302667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:03Z","timestamp":1759062783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220302667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"alternative-id":["S0166354220302667"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104852","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104852"}}